Іспанія - англійська - HMA (Heads of Medicines Agencies)

ceva s.a. - colistin sulfate 2000000 iu/ml - oral solution - chicken, pigs - colistin

США - англійська - NLM (National Library of Medicine)

baxter healthcare corporation - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - gentamicin 60 mg in 50 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin sulfate in 0.9% sodium chloride injection and other antibacterial drugs, gentamicin sulfate in 0.9% sodium chloride injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. gentamicin sulfate in 0.9% sodium chloride injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa , proteus species (indole-positive and indole-negative), escherichia coli , klebsiella-enterobacter- serratia species, citrobacter species, and staphylococcus species (coagulase-positive and coagulase-negative). clinical studies have shown gentamicin sulfate to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. gentamicin sulfate in 0.9% sodium chloride injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. the decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the boxed warnings. if the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. in serious infections when the causative organisms are unknown, gentamicin sulfate in 0.9% sodium chloride injection may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. if anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. gentamicin injection has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by pseudomonas aeruginosa . it has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group d streptococci. gentamicin injection has also been shown to be effective in the treatment of serious staphylococcal infections. while not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgement indicate its use. it may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. in the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin (see precautions, pediatric use and dosage and administration sections). hypersensitivity to gentamicin is a contraindication to its use. a history of hypersensitivity or serious toxic reactions to other aminoglycosides may contraindicate use of gentamicin because of known cross-sensitivity of patients to drugs in this class.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - tobramycin sulfate, quantity: 762.24 mg (equivalent: tobramycin, qty 500 mg) - injection, concentrated - excipient ingredients: sulfuric acid; water for injections; sodium hydroxide - tobra-day is indicated for once daily intravenous use in the treatment of cystic fibrosis patients (greater than 5 years old) with acute pulmonary exacerbations caused by susceptible organisms.

США - англійська - NLM (National Library of Medicine)

golden state medical supply, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg

США - англійська - NLM (National Library of Medicine)

major pharmaceuticals - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297) - neomycin sulfate 500 mg

Бангладеш - англійська - DGDA (Directorate General of Drug Administration)

kemiko pharmaceuticals ltd. - colistin sulphate - powder - 1000 lac iu

США - англійська - NLM (National Library of Medicine)

hospira, inc. - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. gentamicin sulfate injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa , proteus species (indole-positive and indole-negative), escherichia coli , klebsiella-enterobacter-serratia species, citrobacter species, and staphylococcus species (coagulase-positive and coagulase-negative). clinical studies have shown gentamicin sulfate injection, usp to be effective in bacterial neonatal se

США - англійська - NLM (National Library of Medicine)

teva parenteral medicines, inc. - amikacin sulfate (unii: n6m33094fd) (amikacin - unii:84319sgc3c) - amikacin sulfate injection is indicated in the short-term treatment of serious infections due to susceptible strains of gram-negative bacteria, including pseudomonas species, escherichia coli , species of indole-positive and indole-negative proteus , providencia species, klebsiella-enterobacter-serratia species and acinetobacter (mima-herellea ) species. clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including postvascular surgery). clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. aminoglycosides, including amikacin sulfate injection, are not indicated in uncomplicated initial episodes of urinary tract infec

США - англійська - NLM (National Library of Medicine)

cardinal health 107, llc - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. gentamicin sulfate injection, usp is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: pseudomonas aeruginosa, proteus species (indole-positive and indole-negative), escherichia coli, klebsiella-enterobacter-serratia species, citrobacter species, and staphylococcus species (coagulase-positive and coagulase-negative). clinical studies have shown gentamicin sulfate injection, usp to be effective in bacterial neonatal sepsis

Малайзія - англійська - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hong huey sdn bhd - colistin sulphate -